Synairgen plc (SYGGF)
USD 0.04
(-23.64%)
USD 0.04
(-23.64%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -8.4 Million GBP | 52.35% |
| 2022 | -17.64 Million GBP | 63.74% |
| 2021 | -48.66 Million GBP | -249.69% |
| 2020 | -13.91 Million GBP | -258.2% |
| 2019 | -3.88 Million GBP | -17.69% |
| 2018 | -3.3 Million GBP | -287.45% |
| 2017 | 1.76 Million GBP | 162.51% |
| 2016 | -2.81 Million GBP | -24.92% |
| 2015 | -2.25 Million GBP | -289.81% |
| 2014 | 1.18 Million GBP | 158.15% |
| 2013 | -2.04 Million GBP | 9.2% |
| 2012 | -2.25 Million GBP | 30.36% |
| 2011 | -3.23 Million GBP | -26.71% |
| 2010 | -2.55 Million GBP | -2.25% |
| 2009 | -2.49 Million GBP | -15.89% |
| 2008 | -2.15 Million GBP | -31.22% |
| 2007 | -1.64 Million GBP | -56.34% |
| 2006 | -1.04 Million GBP | -71.97% |
| 2005 | -610 Thousand GBP | -298.69% |
| 2004 | -153 Thousand GBP | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 Q2 | -4.74 Million GBP | -199900.0% |
| 2023 Q1 | -2374.00 GBP | 99.95% |
| 2023 FY | -8.4 Million GBP | 52.35% |
| 2023 Q4 | -1830.00 GBP | 0.0% |
| 2023 Q3 | -1830.00 GBP | 99.96% |
| 2022 Q1 | -6203.00 GBP | 99.96% |
| 2022 FY | -17.64 Million GBP | 63.74% |
| 2022 Q4 | -5.23 Million GBP | -199900.0% |
| 2022 Q3 | -2619.50 GBP | 99.98% |
| 2022 Q2 | -12.4 Million GBP | -199900.0% |
| 2021 Q3 | -7872.00 GBP | 99.98% |
| 2021 Q1 | -16.45 Thousand GBP | 99.83% |
| 2021 FY | -48.66 Million GBP | -249.69% |
| 2021 Q2 | -32.91 Million GBP | -199899.99% |
| 2021 Q4 | -15.74 Million GBP | -199900.0% |
| 2020 Q3 | -4977.00 GBP | 99.87% |
| 2020 Q2 | -3.96 Million GBP | -199900.0% |
| 2020 Q1 | -1981.00 GBP | 99.91% |
| 2020 Q4 | -9.95 Million GBP | -199900.0% |
| 2020 FY | -13.91 Million GBP | -258.2% |
| 2019 Q1 | -886.00 GBP | 0.67% |
| 2019 Q3 | -1056.50 GBP | 99.94% |
| 2019 FY | -3.88 Million GBP | -17.69% |
| 2019 Q4 | -2.11 Million GBP | -199900.0% |
| 2019 Q2 | -1.77 Million GBP | -199900.0% |
| 2018 Q3 | -892.00 GBP | -17.6% |
| 2018 Q1 | -758.50 GBP | -150.22% |
| 2018 FY | -3.3 Million GBP | -287.45% |
| 2018 Q2 | -758.50 GBP | 0.0% |
| 2018 Q4 | -892.00 GBP | 0.0% |
| 2017 Q3 | 1510.50 GBP | 339.76% |
| 2017 FY | 1.76 Million GBP | 162.51% |
| 2017 Q4 | 1510.50 GBP | 0.0% |
| 2017 Q1 | -630.00 GBP | 12.2% |
| 2017 Q2 | -630.00 GBP | 0.0% |
| 2016 FY | -2.81 Million GBP | -24.92% |
| 2016 Q2 | -691.00 GBP | 0.0% |
| 2016 Q4 | -717.50 GBP | 0.0% |
| 2016 Q1 | -691.00 GBP | -2.75% |
| 2016 Q3 | -717.50 GBP | -3.84% |
| 2015 Q4 | -672.50 GBP | 0.0% |
| 2015 FY | -2.25 Million GBP | -289.81% |
| 2015 Q3 | -672.50 GBP | -47.8% |
| 2015 Q2 | -455.00 GBP | 0.0% |
| 2015 Q1 | -455.00 GBP | -28.17% |
| 2014 Q2 | 949.00 GBP | 0.0% |
| 2014 Q1 | 949.00 GBP | 293.67% |
| 2014 Q4 | -355.00 GBP | 0.0% |
| 2014 FY | 1.18 Million GBP | 158.15% |
| 2014 Q3 | -355.00 GBP | -137.41% |
| 2013 Q3 | -490.00 GBP | 7.81% |
| 2013 Q1 | -531.50 GBP | 0.0% |
| 2013 Q4 | -490.00 GBP | 0.0% |
| 2013 Q2 | -531.50 GBP | 0.0% |
| 2013 FY | -2.04 Million GBP | 9.2% |
| 2012 FY | -2.25 Million GBP | 30.36% |
| 2011 FY | -3.23 Million GBP | -26.71% |
| 2010 FY | -2.55 Million GBP | -2.25% |
| 2009 FY | -2.49 Million GBP | -15.89% |
| 2008 FY | -2.15 Million GBP | -31.22% |
| 2007 FY | -1.64 Million GBP | -56.34% |
| 2006 FY | -1.04 Million GBP | -71.97% |
| 2005 FY | -610 Thousand GBP | -298.69% |
| 2004 FY | -153 Thousand GBP | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| RegeneRx Biopharmaceuticals, Inc. | -1.72 Million USD | -386.728% |
| CSL Limited | 2.64 Billion USD | 100.318% |
| Eiger BioPharmaceuticals, Inc. | -74.96 Million USD | 88.784% |
| Nanobac Pharmaceuticals, Incorporated | -6.57 Million USD | -27.857% |
| Institute of Biomedical Research Corp. | -273.4 Thousand USD | -2975.325% |
| Evofem Biosciences, Inc. | 52.97 Million USD | 115.87% |
| Santhera Pharmaceuticals Holding AG | 65.13 Million USD | 112.909% |
| Propanc Biopharma, Inc. | -1.82 Million USD | -361.844% |
| Mesoblast Limited | -87.95 Million USD | 90.441% |
| Marizyme, Inc. | -65.34 Million USD | 87.133% |
| Genus plc | 7.9 Million USD | 206.43% |
| VioQuest Pharmaceuticals, Inc. | -10.89 Million USD | 22.804% |
| CNBX Pharmaceuticals Inc. | -3.71 Million USD | -126.616% |
| Nymox Pharmaceutical Corporation | -8.84 Million USD | 4.93% |
| ContraFect Corporation | -65.15 Million USD | 87.095% |
| PsyBio Therapeutics Corp. | -4.88 Million USD | -72.081% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| IMV Inc. | -36.48 Million USD | 76.955% |
| AXIM Biotechnologies, Inc. | -8.05 Million USD | -4.322% |
| MultiCell Technologies, Inc. | -380.07 USD | -2212124.064% |
| Accustem Sciences Inc. | -3.74 Million USD | -124.428% |
| RVL Pharmaceuticals plc | -51.69 Million USD | 83.734% |
| EV Biologics, Inc. | -1.26 Million USD | -563.545% |
| Q BioMed Inc. | -2.05 Million USD | -309.728% |
| Emmaus Life Sciences, Inc. | -3.73 Million USD | -125.234% |
| Mosaic ImmunoEngineering Inc. | -2.38 Million USD | -253.148% |
| Biomind Labs Inc. | -1.21 Million USD | -592.405% |
| Oncotelic Therapeutics, Inc. | -7.9 Million USD | -6.389% |
| Skye Bioscience, Inc. | -37.64 Million USD | 77.665% |
| SQZ Biotechnologies Company | -79.46 Million USD | 89.419% |
| THC Farmaceuticals, Inc. | -14.97 Thousand USD | -56043.162% |
| Arch Therapeutics, Inc. | -6.98 Million USD | -20.41% |
| Intellipharmaceutics International Inc. | -2.89 Million USD | -190.693% |
| Acro Biomedical Co., Ltd. | -15.87 Million USD | 47.024% |
| Neon Bloom, Inc. | -632.4 Thousand USD | -1229.524% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Pharming Group N.V. | -10.54 Million USD | 20.288% |
| Therapeutic Solutions International, Inc. | -2.16 Million USD | -287.499% |
| Curative Biotechnology, Inc. | -5.81 Million USD | -44.536% |
| GB Sciences, Inc. | -1.36 Million USD | -517.474% |
| Alpha Cognition Inc. | -13.77 Million USD | 38.951% |
| argenx SE | -295.05 Million USD | 97.15% |
| HST Global, Inc. | -146.21 Thousand USD | -5650.633% |
| Halberd Corporation | -79.67 Thousand USD | -10452.739% |
| Enzolytics Inc. | -2.17 Million USD | -286.249% |
| Resverlogix Corp. | -3.61 Million USD | -132.909% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| Nuo Therapeutics, Inc. | -3.17 Million USD | -165.116% |
| MetaStat, Inc. | - USD | Infinity% |
| Northwest Biotherapeutics, Inc. | -62.59 Million USD | 86.568% |
| American Oriental Bioengineering, Inc. | -59.72 Million USD | 85.922% |
| Enzon Pharmaceuticals, Inc. | 98 Thousand USD | 8679.592% |
| Provectus Biopharmaceuticals, Inc. | -3.1 Million USD | -171.071% |
| Endonovo Therapeutics, Inc. | 6.92 Million USD | 221.422% |
| GlobeStar Therapeutics Corporation | -1.94 Million USD | -331.346% |
| RespireRx Pharmaceuticals Inc. | -3.97 Million USD | -111.629% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | -3.02 Million USD | -177.846% |
| AVAX Technologies, Inc. | -6.41 Million USD | -31.095% |
| ONE Bio Corp. | 8.67 Million USD | 196.904% |
| Zenith Capital Corp. | -10.59 Million USD | 20.649% |
| Genscript Biotech Corporation | -95.47 Million USD | 91.194% |
| Ember Therapeutics, Inc. | -23.24 Thousand USD | -36075.888% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -4.14 Million USD | -102.801% |
| WPD Pharmaceuticals Inc. | -60.44 Thousand USD | -13811.177% |
| Cotinga Pharmaceuticals Inc. | -2 Million USD | -319.328% |
| Wesana Health Holdings Inc. | -1.75 Million USD | -379.151% |
| Agentix Corp. | -1.37 Million USD | -511.842% |
| Adynxx, Inc. | - USD | Infinity% |
| Kadimastem Ltd | -3.3 Million USD | -154.218% |
| Helix BioMedix, Inc. | -1.05 Million USD | -696.169% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Capstone Therapeutics Corp. | -3.81 Million USD | -120.162% |
| BioStem Technologies, Inc. | -8.48 Million USD | 0.884% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Reve Technologies, Inc. | -441.36 Thousand USD | -1804.982% |
| Burzynski Research Institute, Inc. | -1.33 Million USD | -529.609% |
| LadRx Corporation | 400.44 Thousand USD | 2199.675% |
| Cell Source, Inc. | -5.32 Million USD | -58.009% |
| ProtoKinetix, Incorporated | -415.47 Thousand USD | -1923.688% |
| Regen BioPharma, Inc. | 1.02 Million USD | 921.488% |
| Regen BioPharma, Inc. | 1.02 Million USD | 921.488% |
| NovAccess Global Inc. | -4.76 Million USD | -76.298% |
| Affymax, Inc. | -14.42 Million USD | 41.708% |
| Itoco Inc. | -1.86 Million USD | -349.867% |
| Rasna Therapeutics, Inc. | -4.44 Million USD | -89.261% |
| Pathfinder Cell Therapy, Inc. | -1.66 Million USD | -403.775% |
| CytoDyn Inc. | -49.84 Million USD | 83.13% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -79.03 Thousand USD | -10538.594% |
| NanoSphere Health Sciences Inc. | -228.12 Thousand USD | -3585.666% |
| Qrons Inc. | -789.34 Thousand USD | -965.184% |
| Alseres Pharmaceuticals, Inc. | -941.52 Thousand USD | -793.016% |
| SYBLEU INC | -180.3 Thousand USD | -4563.235% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| Nascent Biotech, Inc. | -2.08 Million USD | -302.743% |
| Rebus Holdings, Inc. | -1.02 Million USD | -724.314% |
| ImmunoCellular Therapeutics, Ltd. | -1.61 Million USD | -421.35% |
| Mobile Lads Corp. | -2.26 Million USD | -271.494% |
| International Stem Cell Corporation | -131 Thousand USD | -6318.321% |
| Bioxytran, Inc. | -4.28 Million USD | -96.449% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -54.27 Thousand USD | -15392.335% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -2.53 Million USD | -232.3% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -48.07 Million USD | 82.51% |
| Adhera Therapeutics, Inc. | -2.11 Million USD | -297.729% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -780.88 Thousand USD | -976.724% |
| Innovation Pharmaceuticals Inc. | -3.16 Million USD | -165.404% |
| Neutra Corp. | -233.46 Thousand USD | -3501.396% |
| Windtree Therapeutics, Inc. | -20.29 Million USD | 58.563% |
| PureTech Health plc | -65.69 Million USD | 87.202% |
| Coeptis Therapeutics, Inc. | -21.26 Million USD | 60.464% |
| IXICO plc | -1.17 Million USD | -613.752% |
| IntelGenx Technologies Corp. | -9.92 Million USD | 15.302% |
| Gelesis Holdings, Inc. | -57.12 Million USD | 85.282% |
| CSL Limited | 2.64 Billion USD | 100.318% |
| Cellectis S.A. | -103.17 Million USD | 91.851% |